Weight loss drugs
The latest news about Weight loss drugs: headlines, AI summaries and the full story from every source.
- China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug Orforglipron
- Blackstone to Provide Pfizer Up to $1.5 Billion for Monthly GLP-1 Development
- Eli Lilly Raises Revenue Forecast Amid Strong Zepbound Sales and Competition from Viking Therapeutics
- FDA Requires Vision Loss Warning Label for GLP-1 Weight-Loss Drugs
- Novonesis Explores Microbiome Supplements to Complement GLP-1 Weight-Loss Treatments
- Eli Lilly Demonstrates Revenue Growth Beyond GLP-1 Weight Loss Drugs
- Eli Lilly Reports Strong Third Quarter Results Driven by GLP-1 Growth and Raises Full-Year Guidance
- UBS Initiates Coverage on Viking Therapeutics with Buy Rating and $94 Price Target
- Employers Weigh Costs and Benefits of GLP-1 Medication Coverage
- Viking Therapeutics Reports Q3 2026 Financial Results and Positive Obesity Pipeline Data
- Eli Lilly's Retatrutide Demonstrates Superior Weight Loss and A1C Reduction Compared to Ozempic in Phase 3 Trial
- Zealand Pharma and Roche Release Phase 2 Topline Data for Amylin Analogue Petrelintide
- Viking Therapeutics Shares Rise Over 30% on Encouraging Weight-Loss Drug Trial Results
- Eli Lilly Reports Strong Results for New Weight Loss Drug
- Eli Lilly's New Weight Loss Drug Shows Significant Results in Clinical Trial
- Eli Lilly's Stock Unaffected by Viking Therapeutics' Strong Clinical Results
- Novo Nordisk Stock Falls After Outlining Long-Term Growth Targets
- Eli Lilly CEO Expresses Optimism for Foundayo's Growth in International Markets
- Lilly CEO Dave Ricks Highlights Growth of Foundayo Oral Weight Loss Pill
- Novo Nordisk Reports Better Weight Loss Results for Experimental Obesity Drug CagriSema Compared to Eli Lilly’s Zepbound
- Berenberg Upgrades Eli Lilly Amid Strong Performance of GLP-1 Drugs
- Eli Lilly Acquires AtaiBeckley for $2.8 Billion to Expand Neuroscience Portfolio
- Novo Nordisk Sues Eli Lilly Over Alleged Misleading Weight Loss Drug Advertising
- Samsung Biologics Acquires PolyPeptide Group in $1.8 Billion Deal
- GLP-1 Weight-Loss Drugs Being Tested on Overweight Cats
- Eli Lilly's Obesity Pill Trails Novo Nordisk in Market Adoption
- Zealand Pharma's Weight-Loss Drug Trial Fails Due to Side Effects
- Eli Lilly Reports Weight Loss Results Across Menopause Stages in Obesity Drug Trial
- Eli Lilly Expands Pipeline Through Strategic Acquisitions in Diversified Therapeutic Areas
- Novo Nordisk Launches Wegovy Weight Loss Pill in UAE, Expanding Beyond US Market
- Novo Nordisk Expands Wegovy's Global Reach Beyond U.S. Market
- Novo Nordisk Reports Strong Q1 Results Driven by Wegovy Weight-Loss Pill
- Eli Lilly Announces Positive News for Shareholders Amid Weight Loss Drug Market Growth
- Eli Lilly Announces Approval for New Oral Weight Loss Drug
- Amazon Launches GLP-1 Weight Loss Program to Simplify Access to Obesity Treatments